- Home
- ESNT vs BBIO Comparison
ESNT vs BBIO Comparison
Compare ESNT & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESNT
- BBIO
- Stock Information
- Founded
- ESNT 2008
- BBIO 2015
- Country
- ESNT Bermuda
- BBIO United States
- Employees
- ESNT N/A
- BBIO N/A
- Industry
- ESNT Property-Casualty Insurers
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- ESNT Finance
- BBIO Health Care
- Exchange
- ESNT Nasdaq
- BBIO Nasdaq
- Market Cap
- ESNT N/A
- BBIO 6.7B
- IPO Year
- ESNT 2013
- BBIO 2019
- Fundamental
- Price
- ESNT $58.72
- BBIO $34.83
- Analyst Decision
- ESNT Buy
- BBIO Strong Buy
- Analyst Count
- ESNT 7
- BBIO 12
- Target Price
- ESNT $61.71
- BBIO $57.09
- AVG Volume (30 Days)
- ESNT 619.4K
- BBIO 3.2M
- Earning Date
- ESNT 05-09-2025
- BBIO 04-29-2025
- Dividend Yield
- ESNT 2.10%
- BBIO N/A
- EPS Growth
- ESNT 5.38
- BBIO N/A
- EPS
- ESNT 6.85
- BBIO N/A
- Revenue
- ESNT $1,242,904,000.00
- BBIO $127,415,000.00
- Revenue This Year
- ESNT $3.71
- BBIO $13.67
- Revenue Next Year
- ESNT $4.58
- BBIO $118.02
- P/E Ratio
- ESNT $8.60
- BBIO N/A
- Revenue Growth
- ESNT 12.00
- BBIO N/A
- 52 Week Low
- ESNT $51.61
- BBIO $21.62
- 52 Week High
- ESNT $65.33
- BBIO $39.47
- Technical
- Relative Strength Index (RSI)
- ESNT 62.18
- BBIO 46.94
- Support Level
- ESNT $57.88
- BBIO $36.85
- Resistance Level
- ESNT $58.91
- BBIO $39.16
- Average True Range (ATR)
- ESNT 1.10
- BBIO 1.47
- MACD
- ESNT 0.36
- BBIO -0.07
- Stochastic Oscillator
- ESNT 89.57
- BBIO 25.61
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.